Dr. Reddy’s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL
Retrieved on:
Wednesday, August 4, 2021
Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.
Key Points:
- Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.
- ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.
- ELYXYB is an oral solution dosage form which makes it convenient for patients to take it immediately upon emergence of migraine attacks.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.